-
Zixin Pharmaceutical has lost money for three consecutive years, what is the reason?
Time of Update: 2022-10-13
Sichuan root, the early production area was affected by drought weather, the attention of merchants increased, and the market rose; Recently, the market situation has stabilized, the overall source of goods is not moving fast, the market price of Sichuan Qi unified goods is about 38 yuan, and the source of goods has entered the actual digestion stage.
-
Shanghai chronic disease health management new exploration: "medical and prevention integration" precision, digitalization, standardization
Time of Update: 2022-10-13
The reporter learned on the same day that in order to reduce the patient's waiting time and contact risk, Shanghai continues to explore a new model of integration of new technologies and chronic disease prevention and treatment, and artificial intelligence voice technology has been applied in the follow-up information collection and management scenarios of patients with chronic diseases.
-
Why has Hainan's gradual abolition of general outpatient clinics in tertiary public hospitals caused widespread concern?
Time of Update: 2022-10-13
This news stems from the "Implementation Plan for Promoting the High-quality Development of Public Hospitals in Hainan Province" issued by the General Office of the Hainan Provincial Government not long ago, which proposes to strictly control the number and scale of tertiary public hospitals in the next three to five years, and gradually cancel the general outpatient clinics in these hospitals.
-
Heparin TOP5 listed pharmaceutical companies Fawei, half a year a total of nearly 10 billion!
Time of Update: 2022-10-13
According to Hepalink's semi-annual report, in the first half of 2022, the company's global sales of enoxaparin sodium preparations exceeded 114 million pieces, and the year-on-year sales volume in domestic sales terminals and overseas markets that have been opened up has achieved double-digit growth, of which the year-on-year sales growth in the US market has reached 184.
-
Two vice presidents of pharmaceutical companies resigned in one day, both less than a year in office!
Time of Update: 2022-10-13
On the same day, Meinian Health announced that Ms. Lin Qing applied to resign as vice president and secretary of the board of directors of the company for personal reasons, and no longer held any position in the company after resignation.
-
Sailing Pharmaceutical: Bone health public welfare + sports, multi-dimensional implementation of corporate mission
Time of Update: 2022-10-13
Join hands with Yunnan Provincial GamesLove with athletes and the publicExercise and bone health support each other, and the importance of sports to improve the bone health of middle-aged and elderly people is self-evident.
-
The seventh batch of national procurement is about to land, and many provinces have issued documents to start preliminary work
Time of Update: 2022-10-13
On August 9, the Procurement Center of the Inner Mongolia Autonomous Region issued the Notice on Preparing for the Implementation of the Results of the Seventh Batch of National Centralized Procurement Drugs.
-
The development of the pharmacy sector continues to improve, and the revenue growth of industry leaders in the second half of the year can be expected
Time of Update: 2022-10-13
The data shows that due to the high base of the epidemic in 2020, short-term financial and other factors, the growth rate of the pharmacy industry continued to decline in the second half of 2021.
-
Rising raw material prices, how should pharmaceutical machinery companies respond?
Time of Update: 2022-10-13
Therefore, in order to cope with the challenge of rising raw material prices, pharmaceutical machinery enterprises should strengthen their operation and management, change from extensive to lean management mode, reduce costs, improve quality, speed up processes and improve capital investment, so as to achieve greater value.
-
The use of digitalization to promote innovative marketing of medicine has become the focus of attention in the industry
Time of Update: 2022-10-13
js?cdnversion='+~(-new Date()/36e5)]; With the implementation of documents such as consistency evaluation, "two-vote system", VAT reform, and the normalization of "4+7" procurement with quantity, traditional pharmaceutical marketing is gradually difficult.
-
Xinjiang: The entire Xinjiang drug inventory can basically ensure the market demand for 30 days
Time of Update: 2022-10-13
On the evening of the 7th, Xinjiang held a press conference on epidemic prevention and control. Tian Chunhai, deputy director of the Xinjiang Drug Administration, said in response to a reporter's que
-
The State Food and Drug Administration on the Publication of the Catalogue of Generic Drug Reference Preparations (60th Batch)
Time of Update: 2022-10-13
After the review and confirmation of the Expert Committee on the Consistency Evaluation of Generic Drugs and Efficacy of the State Drug Administration, the Catalogue of Generic Reference Preparations
-
The Chinese medicine tablet industry maintained a high-speed growth trend, achieving a profit of nearly 7.9 billion yuan in the first half of the year
Time of Update: 2022-10-13
2 billion yuan, continuing to maintain a substantial growth trend; In the second quarter, the profit of the Chinese medicine tablet industry increased by 10.
2 billion yuan, continuing to maintain a substantial growth trend; In the second quarter, the profit of the Chinese medicine tablet industry increased by 10.
-
Online medical insurance payment landed in these cities, pharmacy operation O2O needs to do a good job of 4 points!
Time of Update: 2022-10-13
MiIntranet predicts that the scale of retail pharmacy terminals will rise to 1,150 billion yuan in 2029, and the share of the six major markets of the three major terminals will increase significantly, of which the overall market size of physical pharmacies will reach 750 billion yuan, and its scale growth is bound to drive the rise of O2O scale.
-
Announcement of the State Food and Drug Administration on the revision of the instructions for cefazolin injection
Time of Update: 2022-10-13
The marketing authorization holders of the above-mentioned drugs shall report to the Drug Evaluation Center of the State Drug Administration or the provincial drug supervision and administration department for the record before December 30, 2022 in accordance with the relevant provisions of the Measures for the Administration of Drug Registration and other relevant provisions and in accordance with the requirements for the revision of the instructions of cefazolin injections (see annex).
-
In 2022, the size of this drug market will reach 20 billion yuan!
Time of Update: 2022-10-13
In addition, a large number of domestic drugs are in the clinical trial or application for listing stage, among which the class 1 chemical new drug Ansulfaxin hydrochloride extended-release tablets independently developed by Luye Pharmaceutical Group have submitted a marketing application on June 11, 2021, which is suitable for major depressive disorder.
-
Carry out the pilot work of high-quality development of public hospitals in Shanghai
Time of Update: 2022-10-13
Relevant members of the Municipal Leading Group for Deepening Medical Reform, medical reform offices in various districts, and relevant medical institutions: In order to implement the spirit of the O
-
With the wave of financing for pharmaceutical companies, these areas are attracting much attention
Time of Update: 2022-10-13
On Oct. 7, oncology company Nested Therapeutics announced the completion of a $90 million Series A funding round, which will advance Nested's total funding to $125 million to help develop its next generation of cancer precision medicine drugs.
-
The ophthalmic treatment track has begun, and domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】With the intensification of population aging and the increase in the use of electronic products, age-related eye diseases, metabolism-related eye diseases and fun
-
"Peroxin" withdrew from the Chinese market; The growth of the "troika" is weak; How does Roche continue to shine?
Time of Update: 2022-10-12
196 billion; at present, only Roche Pharmaceutical Pailuoxin and Tebao Bio Hepatitis B infectious hormone Paigebin, two polyethylene glycol interferon α-2b injections are listed, it is worth noting that before Pailokhin was Roche's champion product in China - interferon brand sales champion, and repeatedly exchanged price for volume, prompting its rapid growth in the Chinese market.
